A groundbreaking advance in single-cell technology is revolutionizing how scientists observe immune cell behavior by capturing a more comprehensive and dynamic picture of cellular activity. This innovative method, known as CIPHER-seq, enables researchers to concurrently measure RNA and protein expression within the same individual immune cell, revealing the intricate temporal interplay between genetic instructions and their execution in real-time. By providing unprecedented insight into cytokine activity—a cornerstone of immune communication—this technology promises to deepen our understanding of cancer biology, inflammatory processes, and the mechanisms underpinning treatment resistance, potentially accelerating the development of more precise immunotherapies and enhancing the accuracy of patient response predictions.
Developed through a collaborative effort between the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and teams at the University of California, San Francisco as well as the Helen Diller Family Comprehensive Cancer Center, CIPHER-seq represents a significant step forward in immune profiling. Unlike traditional approaches that primarily focus on RNA sequencing, which captures the “blueprint” of cellular activity, this method integrates multiple layers of biological information by also quantifying proteins both on and within the cell. This layered analysis provides a clearer, more dependable window into cellular function, tracing the direct molecular players responsible for immune responses, including cytokines, the potent signaling proteins critical to immune communication and regulation.
Single-cell RNA sequencing has vastly expanded the horizon of biomedical research by allowing high-throughput characterization of gene expression across thousands of individual cells. However, RNA transcripts alone can provide an incomplete and sometimes misleading portrayal of cellular states, as they represent instructions that do not always correlate with final protein output. This discrepancy is especially pronounced for cytokines—key mediators that dictate immune cell behavior, guide inflammatory responses, and influence tumor dynamics. RNA levels fluctuate rapidly and are transient, while proteins accumulate more slowly and persist longer, creating a temporal disconnect that RNA sequencing alone cannot resolve. Hence, understanding immune responses necessitates an integrative approach combining both RNA and protein data to capture the full biological narrative.
CIPHER-seq addresses this complexity by gently preserving immune cells during processing, thus minimizing artificial stress responses that have confounded earlier methods. Standard preparation techniques can induce mitochondrial stress and other cellular perturbations, thereby polluting data with artifacts that mask authentic biological signals. The gentle preservation employed in CIPHER-seq maintains cells closer to their natural physiological state, ensuring that measurements reflect true cellular function rather than experimental distortion. This refinement is crucial for accurately mapping the nuanced processes by which immune cells activate, communicate, and regulate their environments, especially within the challenging context of cancer and inflammation.
Technically, CIPHER-seq captures a comprehensive immunological snapshot from a single cell by simultaneously profiling the entire transcriptome along with intracellular and surface protein markers, including the cytokines sequestered within cells before secretion. The methodology integrates advanced sequencing protocols with protein detection reagents, enabling the simultaneous measurement of thousands of RNA molecules alongside the phenotypic markers and signaling proteins that define the cell’s current status. This multimodal profiling unveils the precise molecular choreography that governs immune activity, facilitating a detailed reconstruction of how cells respond to stimuli and enact immune functions at the molecular level.
To validate the capabilities of this platform, researchers conducted activation assays whereby immune cells were stimulated and tracked over time. CIPHER-seq successfully detected dynamic increases in the production of critical cytokines such as interferon-gamma and tumor necrosis factor—both central players in modulating immune defense and tumor suppression. Through sophisticated computational algorithms that arrange cells along temporal trajectories of activation, the study observed that RNA levels surged first as cells “planned” their response, followed by a subsequent, modestly delayed rise in protein expression, representing the “execution” phase of immune activity. This sequential timing underscores the value of analyzing both RNA and protein simultaneously to unravel the true dynamics of immune responses.
The ability to monitor cytokines at both the transcriptional and protein levels enhances the granularity with which scientists can understand the mechanisms by which immune cells decide to attack cancer cells, ignore them, or paradoxically support tumor growth through chronic inflammation or immune suppression. By moving beyond static single-layer snapshots to continuous, multimodal timelines, CIPHER-seq empowers researchers to uncover hidden regulatory steps, identify novel biomarkers, and elucidate resistance pathways that have heretofore remained obscured in cancer immunology. These insights have far-reaching implications for advancing immunotherapy—tailoring treatments that are not only more effective but also personalized to a patient’s unique immune landscape.
Justin Taylor, M.D., Sylvester physician-scientist and co-senior author of the study, emphasizes that proteins reveal the actual functional endpoints of immune signaling that RNA alone cannot specify. “RNA gives us clues about where a cell is headed,” Dr. Taylor explains, “but proteins show us where it actually arrives. This clearer picture could significantly refine how immunotherapies are designed and how clinicians anticipate treatment outcomes.” This transformative perspective reconceptualizes immunology research, prioritizing integrated molecular datasets that mirror biological reality rather than relying on partial, indirect proxies of cellular activity.
The implications of CIPHER-seq extend beyond cancer to other immune-mediated diseases characterized by aberrant cytokine activity and immune dysfunction. Chronic inflammatory disorders, autoimmune diseases, and infections could all benefit from this technology’s ability to decode immune cell behavior with greater accuracy and precision. By providing a robust, low-artifact platform that delineates the timing and magnitude of cytokine production and signaling events across heterogeneous immune cell populations, scientists can develop targeted therapeutic strategies that modulate immune responses more effectively and safely.
Moreover, the computational framework accompanying CIPHER-seq analysis leverages advanced bioinformatics to correlate complex data streams from RNA and protein channels, mapping immune cell populations onto activation trajectories and functional states with remarkable resolution. This approach empowers researchers to dissect intercellular heterogeneity, pinpoint subtle regulatory nodes, and predict cellular fates in response to tumor microenvironments or therapeutic interventions. The fusion of experimental and computational innovations embodied by CIPHER-seq marks a milestone for systems immunology, setting new standards for accuracy and depth in single-cell profiling technologies.
Looking ahead, integration of CIPHER-seq with other emerging single-cell technologies, such as spatial transcriptomics and epigenetic profiling, could further enhance our ability to chart immune responses in situ within tissue architectures. Such multimodal profiling at unprecedented scales holds the promise to unveil the spatial and temporal regulatory networks that drive immune evasion, inflammation resolution, and therapeutic resistance. As researchers continue to refine and expand this technology, CIPHER-seq is poised to become an indispensable tool in the arsenal for cancer immunotherapy research and beyond, bridging fundamental biology and clinical application in the quest to decipher and harness the immune system.
In summary, the advent of CIPHER-seq constitutes a transformative advance in single-cell immunology by capturing the dual biochemical narratives of RNA and protein within the same immune cells. This multimodal platform transcends the limitations of prior methodologies by reducing artificial cell stress and revealing the precise sequence of cytokine gene and protein expression during immune activation. Providing an integrative and dynamic portrait of immune cell behavior, CIPHER-seq lays the groundwork for improved immunotherapeutic strategies and more accurate clinical predictions in cancer and other immune-related diseases. The study’s publication in the April 8, 2026 issue of Scientific Reports signals a new era in combining molecular granularity with temporal resolution, fostering a deeper understanding of how immune responses genuinely unfold one cell at a time.
Subject of Research: Immune cell behavior and cytokine signaling profiling using multimodal single-cell sequencing technology
Article Title: CIPHER-seq enables intracellular multimodal profiling of cytokine responses in single immune cells
News Publication Date: April 8, 2026
Web References:
http://dx.doi.org/10.1038/s41598-026-44946-y
Image Credits: Photo by Sylvester Cancer
Keywords: Cancer immunotherapy, Cytokines, Cancer genomics, Genome sequencing, RNA sequencing, Single cell sequencing, Immune cells, Cancer immunology, Immunotherapy
